Modality
Small Molecule
MOA
PLK4i
Target
CDK2
Pathway
STING
GAMesoEpilepsy
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Dec 2031
Phase 1Current
NCT03200342
751 pts·GA
2019-11→2031-12·Terminated
NCT06215130
2,909 pts·GA
2022-12→TBD·Active
3,660 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-245.7y awayPh2 Data· GA
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Termina…
P1/2
Active
Catalysts
Ph2 Data
2031-12-24 · 5.7y away
GA
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03200342 | Phase 1/2 | GA | Terminated | 751 | BodyWt |
| NCT06215130 | Phase 1/2 | GA | Active | 2909 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 |